This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bracke, M. E. Articles by Castronovo, V. Search for Related Content PubMed PubMed Citation Articles by Bracke, M. E. Articles by Castronovo, V.

Tamoxifen Restores the E-Cadherin Function in Human Breast Cancer MCF-7/6 Cells and Suppresses Their Invasive Phenotype¹

Laboratory of Experimental Cancerology, University Hospital, De Pintelaan 185, Gent [M. E. B., E. A. B., C. L., M. M. M.], and Metastasis Research Laboratory, University of Liège, Sart-Tilman-Liège [C. C., V. C.], Belgium

Tamoxifen is an antiestrogen used in adjuvant therapy of breast carcinoma and could potentially prevent the development of mammary cancer. While it is widely clinically used, its exact mechanisms of action are not yet fully elucidated. MCF-7/6 cells are estrogen receptor-positive invasive human breast cancer cells with a functionally inactive cell surface E-cadherin. In this study, we report that tamoxifen, and to a lesser extent its metabolites 4-OH-tamoxifen and N-desmethyl-tamoxifen, restore the function of E-cadherin in MCF-7/6 cells. In an aggregation assay, 10^-6 M tamoxifen significantly increases the aggregation of MCF-7/6 cells. This effect is abrogated by a monoclonal antibody against E-cadherin (HECD-1), is fast (within 30 min), and does not require de novo protein synthesis. Tamoxifen was also found to inhibit the invasion of MCF-7/6 cells in organ culture. Our data is the first demonstration that tamoxifen can activate the function of an invasion suppressor molecule and suggest that the restoration of E-cadherin function may contribute to the therapeutic benefit of tamoxifen in breast cancer patients.

¹ This work was supported by a grant from the Department of Citrus of the State of Florida.

² To whom requests for reprints should be addressed.

Received 5/27/94. Accepted 7/13/94.

This article has been cited by other articles:

				X. Zhang, B. S. Emerald, S. Mukhina, K. M. Mohankumar, A. Kraemer, A. S. Yap, P. D. Gluckman, K.-O. Lee, and P. E. Lobie HOXA1 Is Required for E-cadherin-dependent Anchorage-independent Survival of Human Mammary Carcinoma Cells J. Biol. Chem., March 10, 2006; 281(10): 6471 - 6481. [Abstract] [Full Text] [PDF]

				M. Harigopal, A. J. Berger, R. L. Camp, D. L. Rimm, and H. M. Kluger Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer Clin. Cancer Res., June 1, 2005; 11(11): 4083 - 4089. [Abstract] [Full Text] [PDF]

				L. Li, J. Backer, A. S. K. Wong, E. L. Schwanke, B. G. Stewart, and M. Pasdar Bcl-2 expression decreases cadherin-mediated cell-cell adhesion J. Cell Sci., September 15, 2003; 116(18): 3687 - 3700. [Abstract] [Full Text] [PDF]

				S. Oesterreich, W. Deng, S. Jiang, X. Cui, M. Ivanova, R. Schiff, K. Kang, D. L. Hadsell, J. Behrens, and A. V. Lee Estrogen-mediated Down-Regulation of E-cadherin in Breast Cancer Cells Cancer Res., September 1, 2003; 63(17): 5203 - 5208. [Abstract] [Full Text] [PDF]

				L. Rodriguez-Rodriguez, I. Sancho-Torres, D. G. Gibbon, L. F. Miller Watelet, and C. Mesonero CD44-9v and CD44-10v Are Potential Molecular Markers for Squamous Cell Carcinoma of the Vulva Reproductive Sciences, January 1, 2000; 7(1): 70 - 75. [Abstract] [PDF]

				B. M. FREY, B. F. X. REBER, B. S. VISHWANATH, G. ESCHER, and F. J. FREY Annexin I modulates cell functions by controlling intracellular calcium release FASEB J, December 1, 1999; 13(15): 2235 - 2245. [Abstract] [Full Text]

				N. Altan, Y. Chen, M. Schindler, and S. M. Simon Tamoxifen inhibits acidification in cells independent of the estrogen receptor PNAS, April 13, 1999; 96(8): 4432 - 4437. [Abstract] [Full Text] [PDF]

				E. Pötter, C. Bergwitz, and G. Brabant The Cadherin-Catenin System: Implications for Growth and Differentiation of Endocrine Tissues Endocr. Rev., April 1, 1999; 20(2): 207 - 239. [Abstract] [Full Text]

				M. E. Bracke, H. T. Depypere, T. Boterberg, V. L. Van Marck, K.'l M. Vennekens, E. Vanluchene, M. Nuytinck, R. Serreyn, and M. M. Mareel Influence of Tangeretin on Tamoxifen's Therapeutic Benefit in Mammary Cancer J Natl Cancer Inst, February 17, 1999; 91(4): 354 - 359. [Abstract] [Full Text] [PDF]